ArticleFrontiers in pharmacology2026
Disease severity modifies the ceftazidime-avibactam exposure-response relationship in critically ill patients: a retrospective study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ceftazidime-avibactam (CAZ-AVI) is a key agent for MDR-GNB, but significant pharmacokinetic (PK) variability in critically ill patients poses challenges to achieving optimal dosing. Objectives: To investigate the association and influencing factors between CAZ-AVI serum concentration and clinical efficacy in critically ill patients, and specifically to evaluate the influence of disease severity on this relationship, with the aim of identifying a therapeutic target for critically ill patients with different disease severity. Methods: A retrospective study was conducted of 168 critically ill patients receiving ceftazidime/avibactam between 2021 and 2025. The relationship between plasma drug concentration, clinical efficacy and disease severity was evaluated. Results: 168 patients were included. C Conclusion: This retrospective analysis provides evidence that optimizing CAZ-AVI plasma concentrations is crucial for improving outcomes in critically ill patients, and that this relationship is significantly modulated by disease severity, necessitating a severity-adapted therapeutic drug monitoring (TDM) strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.